Burn injuries pose significant challenges in clinical management, often resulting in long-term complications like scarring and impaired wound healing. Traditional treatments have limitations, spurring exploration into innovative modalities. Induced pluripotent stem cells (iPSCs) offer promise in regenerative medicine by providing personalized and autologous cell sources. This paper assesses iPSC-derived therapies' potential to complement traditional burn treatments. iPSCs, generated from patient somatic cells and differentiated into skin cells, offer a tailored approach to wound healing. Their immunomodulatory properties can mitigate inflammation and reduce rejection risk in allogeneic transplantation. Despite challenges, iPSC-based therapies can revolutionize burn care, improve outcomes, and enhance burn survivors' quality of life. Continued research and advancements in iPSC technology are essential for realizing these approaches' full potential in clinical practice. Burn injuries present complex wound management challenges, requiring innovative approaches. This paper evaluates iPSC-derived therapies' integration into two key aspects of burn treatment: skin grafting and wound dressings. Traditional skin grafting faces limited availability and functional outcomes, which iPSC technology may address by providing patient-specific, functionally enhanced graft material with reduced rejection risk. Similarly, traditional wound dressings have limitations impacting their effectiveness in burn treatment. Advanced dressings incorporating iPSC-derived cells offer active participation in wound healing, promoting tissue regeneration, and minimizing scarring. Preclinical and clinical studies demonstrate iPSC-derived therapies' efficacy in enhancing keratinocyte migration, angiogenesis, and wound closure. These findings underscore iPSC-based therapies' potential to revolutionize burn treatment by addressing key challenges and improving patient outcomes. Future research should focus on refining protocols, conducting large-scale clinical trials, and navigating regulatory pathways to facilitate widespread adoption, ultimately enhancing the quality of life for burn survivors. Addressing scalability, cost, and ethical considerations is paramount for successful integration into clinical practice, requiring collaborative efforts between researchers, clinicians, regulators, and stakeholders.